Neurocrine Closer To Ingrezza Label Expansion With Huntington’s Chorea Phase III Win
Executive Summary
The neuroscience-focused firm plans a 2022 supplemental NDA for Ingrezza following success in the pivotal KINECT-HD study. The biotech needed an R&D success after recent stumbles.
You may also be interested in...
New Player Joins Search For Effective Huntington's Therapies
Despite recent setbacks for Roche and Wave's respective antisense offerings, both those two firms and a number of other companies are trying a variety of approaches to find a treatment for Huntington's.
Neurocrine Gains Clinical-Stage Schizophrenia Candidates Returned To Sosei By AbbVie
Deal Snapshot: Neurocrine expanded its pipeline with rights to subtype-selective muscarinic M4, M1 and dual M1/M4 receptor agonists discovered by Sosei.
Roche Jumps Back Into Huntington’s With Spark/NeuExcell Partnership
Deal Snapshot: Roche gene therapy subsidiary Spark gets option and will partner with start-up NeuExcell on a Huntington’s gene therapy that researchers say may regenerate functional neurons.